Daratumumab in the management of AL amyloidosis

Daratumumab may be a promising treatment for newly-diagnosed patients with light chain (AL) amyloidosis. Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the drug treatment options in AL amyloidosis, specifically focussing on the role of daratumumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).